KLRA
Kailera Therapeutics, Inc.
Key Drivers
- Strong Liquidity
- Heavy Burn
- Asset-Backed Value
AIAI Summary
KLRA has shifted from a cash-survival biotech to a well-funded obesity pipeline story with runway into mid-2028, so the investment case now hinges on proving ribupatide in global Phase 3 and avoiding execution or regulatory delays that could push the value inflection beyond its cash runway.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Liquidity
- •Heavy Burn
- •Asset-Backed Value
KLRA has an exceptionally strong balance sheet and liquidity profile, but zero revenue, persistent losses, and negative cash flow mean its value currently rests on cash and assets rather than operating performance.
Price Behavior
Key Price Behavior Insights:
- •Late-July weakness
- •Early-August rebound
- •Near-term stall
Over the last month, KLRA rebounded from a late-July slide but has since stalled back below $18, leaving it range-bound between $16.7-$17.0 support and $18.9-$19.0 resistance.
Recovered from the mid-$16s to near $19, then quickly pulled back below $18
Sentiment & News
Key News Insights:
- •IND Filed
- •Phase 3 Planned
- •Runway Extended
Kailera Therapeutics advanced its obesity pipeline with an IND filing for oral ribupatide, Phase 3 trial planning for 2027, and a cash runway into mid-2028.
The update is positive for KLRA as it de-risks the obesity program and reinforces funding visibility through key clinical milestones